Nature Reviews Clinical Oncology - Table of Contents alert Volume 11 Issue 5

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
May 2014 Volume 11 Number 5
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Determining the optimal dose in the development of anticancer agents Ron H. J. Mathijssen, Alex Sparreboom & Jaap Verweij
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Clinical Collection on Hepatocellular carcinoma (HCC) This Clinical Collection covers key aspects of the pathogenesis and treatment of HCC, including insights into disease pathways and possible future therapeutic targets.  FREE online  This activity is supported by an educational grant from Lilly.
RESEARCH HIGHLIGHTS Top Screening: Where does stool DNA testing FIT in the CRC screening menu? Published online: 15 April 2014 p239 | doi:10.1038/nrclinonc.2014.60 PDF Imaging: Lighting up tumours Published online: 25 March 2014 p240 | doi:10.1038/nrclinonc.2014.57 PDF Genetics: Serpins' role in brain metastasis uncovered Published online: 18 March 2014 p241 | doi:10.1038/nrclinonc.2014.46 PDF Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ALL Published online: 18 March 2014 p241 | doi:10.1038/nrclinonc.2014.48 PDF Surgery: Stereotactic radiosurgery—new options for multiple brain metastases? Published online: 25 March 2014 p242 | doi:10.1038/nrclinonc.2014.56 PDF Gynaecological cancer: Aurelia—ovarian combination Published online: 01 April 2014 p242 | doi:10.1038/nrclinonc.2014.59 PDF Basic research: Rebooting rhabdomyosarcoma's operating system Published online: 15 April 2014 p242 | doi:10.1038/nrclinonc.2014.62 PDF IN BRIEF Paediatric oncology: Identifying aggressive neuroblastoma | Basic research: Inhibiting autophagy to fight BRAF resistance | Biomarkers: Peeing on a stick | Urological cancer: 'Watch and wait' or 'watch and worry'? PDF Clinical Oncology JOBS of the week Postdoctoral – Department of Molecular Medicine / Oncology Mayo Clinic - Rochester Clinical Professor of Medical Oncology Queen's University Belfast Thoracic / Head & Neck Medical Oncology Faculty Position MD Anderson Cancer Center Postdoctoral Associate University of Texas MD Anderson Cancer Center Postdoctoral Fellowship in Medical Imaging Standford University More Science jobs from Clinical Oncology EVENT 3rd Oncology Partnering & Deal Making 07.07.14 Boston, USA More science events from
NEWS AND VIEWS		Top
Targeted therapies: Further delineating bevacizumab's response spectrum David A. Reardon & Patrick Y. Wen Published online: 08 April 2014 p243 | doi:10.1038/nrclinonc.2014.61 The use of antiangiogenic drugs, such as bevacizumab, represents an appealing intervention against cancer. However, not all malignancies are equally responsive to such treatment. Recent trials demonstrate the efficacy of this drug for advanced-stage cervical cancer and, despite limitations, bevacizumab provides an important clinical respite for most patients with progressive glioblastoma. Full Text | PDF
Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? James C. Yang, Richard M. Sherry & Steven A. Rosenberg Published online: 15 April 2014 p245 | doi:10.1038/nrclinonc.2014.65 A large definitive trial comparing the use of sentinel lymph node biopsy and elective lymph node dissection to observation in patients with intermediate thickness melanomas fails to show improved melanoma-specific survival. These results demand reconsideration of the routine use of sentinel lymph node biopsy in the treatment of primary melanoma. Full Text | PDF
Melanoma: MSLT-1—putting sentinel lymph node biopsy into context Vernon K. Sondak & Jonathan S. Zager Published online: 15 April 2014 p246 | doi:10.1038/nrclinonc.2014.66 The MSLT-1 study compared sentinel lymph node biopsy (SLNB) with nodal observation in patients with localized cutaneous melanoma. The final results of the trial—conducted from 1994 to 2002—strongly support using SLNB in staging patients with melanomas ≥1.0 mm in thickness, but the optimal staging approach for thinner melanomas is unanswered. Full Text | PDF
Melanoma: MSLT-1—SNB is a biomarker, not a therapeutic intervention Alexander C. J. van Akkooi & Alexander M. M. Eggermont Published online: 08 April 2014 p248 | doi:10.1038/nrclinonc.2014.64 The final analysis of the MSLT-1 trial confirms that sentinel lymph node biopsy (SNLB) does not improve survival in patients with melanoma >1 mm thickness. Subgroup analyses remain inconclusive. SNLB provides prognostic information for adjuvant therapy decisions, as recent data indicate that adjuvant therapies are effective in patients with positive sentinel nodes with an ulcerated primary. Full Text | PDF
REVIEWS		Top
Building capacity for sustainable research programmes for cancer in Africa Isaac Adewole, Damali N. Martin, Makeda J. Williams, Clement Adebamowo, Kishor Bhatia, Christine Berling, Corey Casper, Karima Elshamy, Ahmed Elzawawy, Rita T. Lawlor, Rosa Legood, Sam M. Mbulaiteye, Folakemi T. Odedina, Olufunmilayo I. Olopade, Christopher O. Olopade, Donald M. Parkin, Timothy R. Rebbeck, Hana Ross, Luiz A. Santini, Julie Torode, Edward L. Trimble, Christopher P. Wild, Annie M. Young & David J. Kerr Published online: 11 March 2014 p251 | doi:10.1038/nrclinonc.2014.37 In September 2012, over 100 experts in cancer research in Africa met in London to discuss the challenges in carrying out high-quality research in this continent. This Review summarizes the discussions and recommendations of this meeting and many examples of successful programmes that have enhanced the development of research in Africa. It also discusses the next steps required to create programmes that will enable evidenced-based cancer control approaches. Abstract | Full Text | PDF
Li-Fraumeni syndrome: cancer risk assessment and clinical management Kate A. McBride, Mandy L. Ballinger, Emma Killick, Judy Kirk, Martin H. N. Tattersall, Rosalind A. Eeles, David M. Thomas & Gillian Mitchell Published online: 18 March 2014 p260 | doi:10.1038/nrclinonc.2014.41 Individuals with Li-Fraumeni syndrome, who carry germline mutations in the TP53 gene that encodes the tumour-suppressor protein p53, are at high risk of developing cancers in multiple organs. In this Review, considerations for cancer screening and management in carriers of TP53 mutations are discussed, and an evidence-based approach to cancer surveillance in such individuals is proposed. Abstract | Full Text | PDF
Determining the optimal dose in the development of anticancer agents Ron H. J. Mathijssen, Alex Sparreboom & Jaap Verweij Published online: 25 March 2014 p272 | doi:10.1038/nrclinonc.2014.40 Identification of the optimal dose remains a key challenge in drug development. The standard approach that is based on identifying the maximum tolerated dose does not take into account important aspects of clinical pharmacology for newer targeted agents. The authors discuss adaptations to dose-finding trials for molecularly-targeted agents that enable more-efficient trials in the future in terms of costs and, most importantly, optimal patient benefit. Abstract | Full Text | PDF
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy Peter M. Wilson, Peter V. Danenberg, Patrick G. Johnston, Heinz-Josef Lenz & Robert D. Ladner Published online: 15 April 2014 p282 | doi:10.1038/nrclinonc.2014.51 Chemotherapeutic agents targeting thymidylate biosynthesis, and particularly the enzyme thymidylate synthase, have now been key cancer therapies for 60 years. In this article, the classic and novel approaches to targeting this metabolic pathway and strategies for overcoming drug resistance mechanisms are comprehensively reviewed. Abstract | Full Text | PDF
Advertisement
Partnerships that drive high impact open science  Nature Partner Journals is a new series of online open access journals published in collaboration with world-renowned international partners. Each partnership in the portfolio brings together strong editorial leadership with world-class publication systems to deliver high-quality, peer-reviewed original research.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.